CC 90010
According to the NCI website, the BET inhibitor CC-90010 is a bifunctional fusion protein composed of avelumab, an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Check for active clinical trials using this agent. (NCI Thesaurus)
More Information in English: